Related Experiment Videos
Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie
A J Paul1, D E Hutchens, L D Firkins
1Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, 2001 S. Lincoln Avenue, Urbana, IL 61802, USA. a-paul@uiuc.edu
Veterinary Parasitology
|May 12, 2004
Summary
This study found that imidacloprid/moxidectin topical solution is safe for ivermectin-sensitive collies. Even at five times the recommended dose, no signs of toxicosis were observed in treated dogs.
Area of Science:
- Veterinary Dermatology
- Parasitology
- Toxicology
Background:
- Collies are known for their sensitivity to ivermectin, a common antiparasitic drug.
- The combination of imidacloprid and moxidectin is used in topical solutions for flea and tick prevention.
- Assessing the safety of new parasiticides in sensitive breeds is crucial for veterinary practice.
Purpose of the Study:
- To evaluate the safety of a 10% imidacloprid/2.5% moxidectin topical solution in ivermectin-sensitive collies.
- To determine if dosages up to five times the maximum recommended dose cause adverse effects in this sensitive population.
Main Methods:
- Twenty-one ivermectin-sensitive, heartworm-negative collies were enrolled.
- Dogs were assigned to treatment groups receiving 3x or 5x the recommended dose of imidacloprid/moxidectin or mineral oil control.
- Dermal applications were administered on specific days, with blinded observations for clinical signs of toxicosis.
Main Results:
- No signs of toxicosis or adverse effects were observed in any dogs throughout the study period.
- Clinical signs of ivermectin sensitivity were monitored closely and did not manifest in any treatment group.
Conclusions:
- The 10% imidacloprid/2.5% moxidectin topical solution is safe for dermal application in ivermectin-sensitive collies.
- The product can be used at dosages up to five times the maximum recommended dose without causing adverse effects in this breed.